Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 101–200 of 1,018
Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity
Schupp, M., Janke, J., Clasen, R., Unger, T., & Kintscher, U. (2004) · Circulation · doi:10.1161/01.cir.0000127955.36250.65 · Cited by 705
Diabetes and hypertension: the bad companions
Ferrannini, E., & Cushman, W. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60987-8 · Cited by 695
Rothwell, P. M., Howard, S. C., Dolan, E., O'Brien, E., Dobson, J. E., Dahlöf, B., Poulter, N. R., & Sever, P. S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70066-1 · Cited by 690
Self-citationDaskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K., Cloutier, L., Gelfer, M., Lamarre-Cliche, M., Milot, A., Bolli, P., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.016 · Cited by 684
Oparil, S., Zaman, M. A., & Calhoun, D. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-9-200311040-00011 · Cited by 680
Self-citationCentral blood pressure: current evidence and clinical importance
McEniery, C. M., Cockcroft, J. R., Roman, M. J., Franklin, S. S., & Wilkinson, I. B. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht565 · Cited by 678
Writing Committee Members, Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., et al. (2006) · Europace · doi:10.1093/europace/eul097 · Cited by 667
Okin, P. M. (2004) · JAMA · doi:10.1001/jama.292.19.2343 · Cited by 663
Self-citationRenin-angiotensin system and cardiovascular risk
Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60242-6 · Cited by 663
Konstam, M. A., Neaton, J. D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F. A., Riegger, G. A., Malbecq, W., Smith, R. D., Guptha, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61913-9 · Cited by 646
Authors/Task Force Members, Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl176 · Cited by 644
Renin‐angiotensin system revisited
Fyhrquist, F., & Saijonmaa, O. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01981.x · Cited by 642
Self-citationEuropean Stroke Initiative Recommendations for Stroke Management – Update 2003
(2003) · Cerebrovascular Diseases · doi:10.1159/000072554 · Cited by 635
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R. A., Roniker, B., Kleiman, J., Krause, S., Burns, D., & Williams, G. H. (2003) · Circulation · doi:10.1161/01.cir.0000091405.00772.6e · Cited by 623
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31821daaf6 · Cited by 614
Self-citationGarber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
VI Diretrizes Brasileiras de Hipertensão
(2010) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2010001700001 · Cited by 596
Drugs: A review of promising novel corrosion inhibitors
Gece, G. (2011) · Corrosion Science · doi:10.1016/j.corsci.2011.08.006 · Cited by 565
Ibsen, H., Olsen, M. H., Wachtell, K., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlöf, B., Devereux, R. B., de Faire, U., Fyhrquist, F., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000154082.72286.2a · Cited by 562
Self-citationAtenolol in hypertension: is it a wise choice?
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17355-8 · Cited by 562
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Wachtell, K., Ibsen, H., Olsen, M. H., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlf, B., Devereux, R. B., Beevers, G., de Faire, U., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00008 · Cited by 557
Self-citation(2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.002 · Cited by 557
Self-citationHunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
Sandset, E. C., Bath, P. M., Boysen, G., Jatuzis, D., Kõrv, J., Lüders, S., Murray, G. D., Richter, P. S., Roine, R. O., Terént, A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60104-9 · Cited by 541
Rashid, P., Leonardi-Bee, J., & Bath, P. (2003) · Stroke · doi:10.1161/01.str.0000092488.40085.15 · Cited by 530
Santos, R. A. S., Ferreira, A. J., Verano-Braga, T., & Bader, M. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0341 · Cited by 523
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Ann Forciea, M., Frishman, W. H., Jaigobin, C., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.008 · Cited by 514
Self-citationHandelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Ferrario, C. M., & Strawn, W. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.059 · Cited by 512
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., Norgiolini, S., Bracco, C., & Porcellati, C. (2004) · Hypertension · doi:10.1161/01.hyp.0000125726.92964.ab · Cited by 510
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach
Tepel, M., Aspelin, P., & Lameire, N. (2006) · Circulation · doi:10.1161/circulationaha.105.595090 · Cited by 506
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Brandt, M. C., Mahfoud, F., Reda, S., Schirmer, S. H., Erdmann, E., Böhm, M., & Hoppe, U. C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.034 · Cited by 501
Staessen, J. A., Wang, J.-G., & Thijs, L. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00002 · Cited by 487
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
Sipahi, I., Debanne, S. M., Rowland, D. Y., Simon, D. I., & Fang, J. C. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70106-6 · Cited by 481
Metabolic syndrome: Definition, pathophysiology, and mechanisms
Miranda, P. J., DeFronzo, R. A., Califf, R. M., & Guyton, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.013 · Cited by 479
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub5 · Cited by 474
The impact of serum uric acid on cardiovascular outcomes in the LIFE study
Høieggen, A., Alderman, M. H., Kjeldsen, S. E., Julius, S., Devereux, R. B., de Faire, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00484.x · Cited by 473
Self-citationInsulin resistance and hypertension
Sowers, J. R. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00026.2004 · Cited by 471
Devereux, R. B., Dahlöf, B., Gerdts, E., Boman, K., Nieminen, M. S., Papademetriou, V., Rokkedal, J., Harris, K. E., Edelman, J. M., & Wachtell, K. (2004) · Circulation · doi:10.1161/01.cir.0000141573.44737.5a · Cited by 470
Self-citationACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.018 · Cited by 467
Effects of tempol and redox-cycling nitroxides in models of oxidative stress
Wilcox, C. S. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.003 · Cited by 465
Diabetes, hyperglycaemia, and acute ischaemic stroke
Luitse, M. J., Biessels, G. J., Rutten, G. E., & Kappelle, L. J. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70005-4 · Cited by 463
Furuhashi, M., Ura, N., Higashiura, K., Murakami, H., Tanaka, M., Moniwa, N., Yoshida, D., & Shimamoto, K. (2003) · Hypertension · doi:10.1161/01.hyp.0000078490.59735.6e · Cited by 461
van Vark, L. C., Bertrand, M., Akkerhuis, K. M., Brugts, J. J., Fox, K., Mourad, J.-J., & Boersma, E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs075 · Cited by 460
Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function
KASCHINA, E., & UNGER, T. (2003) · Blood Pressure · doi:10.1080/08037050310001057 · Cited by 458
Abuissa, H., Jones, P. G., Marso, S. P., & O’Keefe, J. H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.051 · Cited by 452
Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Sjølie, A. K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61412-9 · Cited by 451
Staessen, J. A., Wang, J., Bianchi, G., & Birkenhäger, W. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13302-8 · Cited by 446
Oparil, S., Yarows, S. A., Patel, S., Fang, H., Zhang, J., & Satlin, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61124-6 · Cited by 444
Self-citationMechanisms of Sympathetic Activation in Obesity-Related Hypertension
Esler, M., Straznicky, N., Eikelis, N., Masuo, K., Lambert, G., & Lambert, E. (2006) · Hypertension · doi:10.1161/01.hyp.0000242642.42177.49 · Cited by 443
Flack, J. M., Sica, D. A., Bakris, G., Brown, A. L., Ferdinand, K. C., Grimm, R. H., Hall, W. D., Jones, W. E., Kountz, D. S., Lea, J. P., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.152892 · Cited by 443
Kjeldsen, S. E., Dahlöf, B., Devereux, R. B., Julius, S., Aurup, P., Edelman, J., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., et al. (2002) · JAMA · doi:10.1001/jama.288.12.1491 · Cited by 443
Self-citationValidity of composite end points in clinical trials
Montori, V. M., Permanyer-Miralda, G., Ferreira-González, I., Busse, J. W., Pacheco-Huergo, V., Bryant, D., Alonso, J., Akl, E. A., Domingo-Salvany, A., Mills, E., et al. (2005) · BMJ · doi:10.1136/bmj.330.7491.594 · Cited by 442
Drugs targeting the renin–angiotensin–aldosterone system
Zaman, M. A., Oparil, S., & Calhoun, D. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd873 · Cited by 439
Self-citationDouglas, J. G. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.525 · Cited by 438
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. (2006) · Circulation · doi:10.1161/circulationaha.106.655688 · Cited by 437
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.812549 · Cited by 426
Self-citationVascular Endothelial Function and Hypertension: Insights and Directions
Dharmashankar, K., & Widlansky, M. E. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0150-2 · Cited by 424
Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition
Schneider, M. P., Hua, T. A., Böhm, M., Wachtell, K., Kjeldsen, S. E., & Schmieder, R. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.043 · Cited by 417
Self-citationThe adipose-tissue renin–angiotensin–aldosterone system: role in the metabolic syndrome?
Engeli, S., Schling, P., Gorzelniak, K., Boschmann, M., Janke, J., Ailhaud, G., Teboul, M., Massiéra, F., & Sharma, A. M. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00311-4 · Cited by 415
Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
(2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280bad9b4 · Cited by 414
Vascular Complications of Diabetes
Beckman, J. A., & Creager, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306884 · Cited by 412
Obesity-Related Hypertension: Epidemiology, Pathophysiology, and Clinical Management
Kotchen, T. A. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.172 · Cited by 410
Maggioni, A. P., Latini, R., Carson, P. E., Singh, S. N., Barlera, S., Glazer, R., Masson, S., Cerè, E., Tognoni, G., & Cohn, J. N. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.033 · Cited by 409
Fliser, D., Buchholz, K., & Haller, H. (2004) · Circulation · doi:10.1161/01.cir.0000140265.21608.8e · Cited by 404
Berl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Parikh, C. R., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00010 · Cited by 402
Young, J. B., Dunlap, M. E., Pfeffer, M. A., Probstfield, J. L., Cohen-Solal, A., Dietz, R., Granger, C. B., Hradec, J., Kuch, J., McKelvie, R. S., et al. (2004) · Circulation · doi:10.1161/01.cir.0000146819.43235.a9 · Cited by 400
Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Ma, L.-J., Mao, S.-L., Taylor, K. L., Kanjanabuch, T., Guan, Y., Zhang, Y., Brown, N. J., Swift, L. L., McGuinness, O. P., Wasserman, D. H., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.2.336 · Cited by 397
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., et al. (2002) · Journal of Hypertension · doi:10.1097/00004872-200209000-00035 · Cited by 392
Self-citationLiu, L., Zhang, Y., Liu, G., Li, W., Zhang, X., & Zanchetti, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000194120.42722.ac · Cited by 392
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II
Lüscher, T. F., Creager, M. A., Beckman, J. A., & Cosentino, F. (2003) · Circulation · doi:10.1161/01.cir.0000089189.70578.e2 · Cited by 391
(2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.020 · Cited by 384
Angiogenesis after cerebral ischemia
Beck, H., & Plate, K. H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0483-6 · Cited by 383
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 373
The Hypertension Paradox — More Uncontrolled Disease despite Improved Therapy
Chobanian, A. V. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0903829 · Cited by 372
Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction
Klapholz, M., Maurer, M., Lowe, A. M., Messineo, F., Meisner, J. S., Mitchell, J., Kalman, J., Phillips, R. A., Steingart, R., Brown, E. J., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.040 · Cited by 371
Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status
Ma, T. K., Kam, K. K., Yan, B. P., & Lam, Y. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00750.x · Cited by 364
Jaffe, I. Z., & Mendelsohn, M. E. (2005) · Circulation Research · doi:10.1161/01.res.0000159937.05502.d1 · Cited by 358
(2007) · Blood Pressure · doi:10.1080/08037050701461084 · Cited by 357
Self-citationHermann, M., Flammer, A., & Lüscher, T. F. (2006) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.06032.x · Cited by 354
Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?
Baker, J. F., Krishnan, E., Chen, L., & Schumacher, H. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.03.043 · Cited by 354
Bangalore, S., Kumar, S., Kjeldsen, S. E., Makani, H., Grossman, E., Wetterslev, J., Gupta, A. K., Sever, P. S., Gluud, C., & Messerli, F. H. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70260-6 · Cited by 353
Self-citationAthyros, V. G., Mikhailidis, D. P., Papageorgiou, A. A., Symeonidis, A. N., Pehlivanidis, A. N., Bouloukos, V. I., & Elisaf, M. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.012989 · Cited by 353
Guidelines for the management of arterial hypertension
van de Borne, P. (2014) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.2143/ac.69.1.3011345 · Cited by 350
Schulzke, S. M., Deshpande, G. C., & Patole, S. K. (2007) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.161.6.583 · Cited by 350
Lambert, G. W., Straznicky, N. E., Lambert, E. A., Dixon, J. B., & Schlaich, M. P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.002 · Cited by 347
Mochizuki, S., Dahlöf, B., Shimizu, M., Ikewaki, K., Yoshikawa, M., Taniguchi, I., Ohta, M., Yamada, T., Ogawa, K., Kanae, K., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60669-2 · Cited by 347
Self-citationRetractedWhat is the optimal serum potassium level in cardiovascular patients?
Macdonald, J. E., & Struthers, A. D. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.06.021 · Cited by 345
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177031 · Cited by 345
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L., Appel, L. J., Benjamin, E. J., Berra, K., Chandra-Strobos, N., Fabunmi, R. P., Grady, D., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000114834.85476.81 · Cited by 344
Self-citationBlood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren
Stanton, A., Jensen, C., Nussberger, J., & O'Brien, E. (2003) · Hypertension · doi:10.1161/01.hyp.0000101688.17370.87 · Cited by 341
Arendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice
Gurley, S. B., Allred, A., Le, T. H., Griffiths, R., Mao, L., Philip, N., Haystead, T. A., Donoghue, M., Breitbart, R. E., Acton, S. L., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci16980 · Cited by 334
Weir, C. J., Muir, S. W., Walters, M. R., & Lees, K. R. (2003) · Stroke · doi:10.1161/01.str.0000081983.34771.d2 · Cited by 334
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.